UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

Cancer science, 2016-12, Vol.107 (12), p.1843-1850

2016

Volltextzugriff (PDF)

Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer

The New England journal of medicine, 2019-06, Vol.380 (24), p.2382-2382

2019

Volltextzugriff (PDF)

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

Breast cancer (Tokyo, Japan), 2020-05, Vol.27 (3), p.322-331

2020

Volltextzugriff (PDF)

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Network Meta‐Analysis

The oncologist (Dayton, Ohio), 2019-06, Vol.24 (6), p.e347-e357

2019

Volltextzugriff (PDF)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

Cancer science, 2022-09, Vol.113 (9), p.3169-3179

2022

Volltextzugriff (PDF)

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Supportive care in cancer, 2015-04, Vol.23 (4), p.1137-1143

2015

Volltextzugriff (PDF)

Assessment of a cancer genomic profile test for patients with metastatic breast cancer

Scientific reports, 2022-03, Vol.12 (1), p.4813-4813, Article 4813

2022

Volltextzugriff (PDF)

Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)

European journal of cancer (1990), 2022-08, Vol.171, p.193-202

2022

Volltextzugriff (PDF)

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

The lancet oncology, 2016, Vol.17 (1), p.90-98

2016

Volltextzugriff (PDF)

Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer

Cancer science, 2017-05, Vol.108 (5), p.853-858

2017

Volltextzugriff (PDF)

Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin

Breast cancer research : BCR, 2023-02, Vol.25 (1), p.21-21, Article 21

2023

Volltextzugriff (PDF)

Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer

BMC cancer, 2024-09, Vol.24 (1), p.1156-7, Article 1156

2024

Volltextzugriff (PDF)

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

BMC cancer, 2019-10, Vol.19 (1), p.980-10, Article 980

2019

Volltextzugriff (PDF)

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study

Journal of clinical oncology, 2020-02, Vol.38 (6), p.558-566

2020

Volltextzugriff (PDF)

Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study

Biological and Pharmaceutical Bulletin, 2024/02/10, Vol.47(2), pp.411-416

2024

Volltextzugriff (PDF)

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Breast cancer research and treatment, 2020-02, Vol.180 (1), p.135-146

2020

Volltextzugriff (PDF)

Effectiveness of self-help workbook intervention on quality of life in cancer patients receiving chemotherapy: results of a randomized controlled trial

BMC cancer, 2021-05, Vol.21 (1), p.1-588, Article 588

2021

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-10, Vol.23 (28), p.6829-6837

2005

Volltextzugriff (PDF)

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5589-5595

2008

Volltextzugriff (PDF)

Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)

Breast (Edinburgh), 2023-10, Vol.71, p.22-28

2023

Volltextzugriff (PDF)

Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma

Medical molecular morphology, 2018-03, Vol.51 (1), p.57-63

2018

Volltextzugriff (PDF)

Systemic therapy for metastatic breast cancer

Annals of oncology, 2019-10, Vol.30, p.vi61

Takano, Toshimi

2019

Volltextzugriff (PDF)

EL25Systemic therapy for metastatic breast cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_6)

Takano, Toshimi

2019

Volltextzugriff (PDF)

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

Breast cancer (Tokyo, Japan), 2023-07, Vol.30 (4), p.596-605

2023

Volltextzugriff (PDF)

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients

BMC cancer, 2020-04, Vol.20 (1), p.325-7, Article 325

2020

Volltextzugriff (PDF)

1 – 25 von 308

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(282)
Mit Volltextzugriff
(282)

Publikationsform

Sprache

Englisch
(288)
Japanisch
(30)

Erscheinungsjahr

n.n

Thema

Science & Technology
(152)
Life Sciences & Biomedicine
(151)
Oncology
(116)
Humans
(114)
Female
(81)
Breast Cancer
(68)
Chemotherapy
(65)
Middle Aged
(49)
Medicine
(48)
Medicine & Public Health
(47)
Aged
(46)
Cancer Research
(44)
Adult
(40)
Patients
(40)
Metastasis
(37)
Surgical Oncology
(37)
Breast Neoplasms - Drug Therapy
(36)
Male
(35)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(31)
Cancer Therapies
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(50)
Annals Of Oncology
(22)
Cancer Research
(22)
The New England Journal Of Medicine
(21)
Breast Cancer
(17)
International Journal Of Clinical Oncology
(17)
Bmc Cancer
(10)
Japanese Journal Of Clinical Oncology
(7)
Cancer Medicine
(6)
The Lancet
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Network Meta‐Analysis

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Assessment of a cancer genomic profile test for patients with metastatic breast cancer

Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer

Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin

Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study

Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Effectiveness of self-help workbook intervention on quality of life in cancer patients receiving chemotherapy: results of a randomized controlled trial

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)

Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma

Systemic therapy for metastatic breast cancer

EL25Systemic therapy for metastatic breast cancer

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients

Suchergebnisse filtern